Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (759)	5/6/1998 10:30:00 AM
From: whitephosphorus	Respond to of 2135

ACEL is in Phase III for cancer,,,READ ON gilbrazil May 5 1998 12:11PM EDTThe situation with ENMD is the same as Alfacell early on - big claims, but with results years away. Alfacell got up in the 20s, then over time came down to 2 1/2. Many of those who bought ENMD in the 80s, 70s, 60s will hold on and get as frustrated as long term Alfacell investors are now. When actual results begin to trickle in the public will react. If human trials prove as effective as with mice ENMD will soar again. Otherwise it will continue to fall. Alfacell is past all that. The drug has already shown efficacy in phase II. The enthusiasm of the past couple of weeks demonstrates that money is watching and starting to react. There will be profit-taking corrections, of course, as we have already seen. But the stock is now following a nice upward path. IMO, continue to buy on dips. Gil ÿ